Try our Advanced Search for more refined results
Life Sciences - May, 2012
259 articles
- Aerospace Deal Crucial To FCC OK For Wireless Medical Tech
- St. Jude Pumps Out $4M To End Heart Implant FCA Suit
- Q&A With Birch Stewart's MaryAnne Armstrong
- GSK Says La. Can't Use Outside Attys In $12B Avandia Suit
- Pfizer, Teva Reach Licensing Deal For Generic Zyvox
- SEC Sues Unico, Advanced Cell Over Alleged Stock Scheme
- AstraZeneca To Settle Toprol-XL Antitrust Action
- Lawmakers Brawl Over Bill To Repeal ACA Medical Device Tax
- Human Genome's Poison Pill Survives As GSK Eyes Coup
- AstraZeneca V. EC — The Advocate General's Opinion
- Barr Urges Calif. High Court To Heed Feds On Pay-For-Delay
- GSK Can't Escape Classen's Patent Infringement Suit
- House Handily Approves Sprawling FDA Reform Bill
- Pfizer Off Hook In Prempro Breast Cancer Case
- Shire Looks To Quash Mylan's Generic Colitis Drug
- Olympus Quells Contract Feud With Ousted CEO
- Tekmira Seeks DQ Of McDermott For Past Patent Work
- Lawmaker Blasts NIH For Funding Doc With Glaxo Conflict
- Tried And True Summary Judgment In Failure-To-Warn Cases
- Caraco V. Novo Nordisk: Antitrust Implications
- Q&A With Fish & Richardson's Juanita Brooks
- Pronova Defeats Teva, Par In Lovaza Patent Suit
- FDA Warns J&J It Can't Slip Away From K-Y Complaints
- Justices Reject Saint-Gobain's Bid For Higher Infringement Bar
- Haynes And Boone Lures Nixon Peabody IP Pro To NY
- Mylan, Sunovion Reach Terms In Xopenex Patent Fight
- Bingham Ramps Up Tech Ranks With Ex-DLA Piper Partner
- St. Jude Loses Occlutech Heart Implant IP Row In The Hague
- Watson, Endo Settle Generic Lidoderm Patent Suit
- Human Genome's Resistance To $2.6B GSK Offer Draws Fire
- Q&A With Sutherland's Bill Warren
- National Cancer Institute Cleared In Contracting Battle
- Dewey & LeBoeuf Files For Bankruptcy
- Allergan, Others Look To Ice Apotex Monopoly Suit
- NY Grand Jury Pins Pain Pill Abuse On Drugmakers, Doctors
- Human Genome Denies Hiding Suicide Risks In Lupus Drug Case
- House Hopes To Cut FDA Bill Costs With Biosimilars Provision
- GOP House Leader Seeks June Vote On Device Tax Repeal
- Q&A With Epstein's Wendy Goldstein
- Tightening FDA Nanotech Regs On Food, Cosmetics
- Europe Clears Roche Cancer Drug After Contamination Report
- Takeda Puts Up $247M For Brazilian Drugmaker Multilab
- Study Links Calcium Products To Higher Heart Risks
- Lab Tied To Eye Infections Halts Sterile Drug Production
- DLA Piper Plucks Latham Tech M&A Ace For Silicon Valley
- FDA User Fee Bill Easily Slides Through Senate
- Combined Prior Art Nixes Joint Patent, Fed. Circ. Rules
- Astellas Sues To Block Hospira's Generic Adenoscan
- FCC Dedicates Spectrum For Wireless Medical Devices
- Broadening Enforcement Of FDA Clinical Investigator Rule
- Q&A With Blank Rome's Terry Henry
- FDA Panel Won't Back J&J's Xarelto For ACS Patients
- Senate To Vote On Pay-For-Delay, 16 Other FDA Changes
- NJ Panel Advances Bill Speeding Class Cert. Appeals
- White House Orders Gov't Agencies To Take Data Mobile
- Dexatrim Maker Says Suit Doesn't Show Harm From Carcinogen
- Q&A With Nixon Peabody's Areta Kupchyk
- Lathrop & Gage Snags 2 Abbott Labs Attys For IP Practice
- UK Teddy Bear Co. Sues J&J Unit Over Misleading Zyrtec Ad
- Clarifying Infringement Liability Under Hatch-Waxman
- J&J Unit Targets Haupt, Ranbaxy Birth Control Generics
- House Dem Pushes Bill Targeting Gray-Market Drug Sales
- Stryker Not Liable For Man's Cartilage Damage, 6th Circ. Says
- Judge Bars Mylan's Oracea Generic In Galderma IP Case
- Judge Won't Reconsider CEO Liability For J&J Recalls
- No Deal Yet On National Drug Track-And-Trace System
- US Liable For Destroyed HIV Samples, Co. Tells 7th Circ.
- Bipartisan FDA User Fee Bill Hits Snag On Senate Floor
- Q&A With Bracewell's Michael Samardzija
- An Unprecedented Settlement For FDCA Violation
- An 'Obvious' Ruling In Abilify Composition Patent Case
- FDA Seizes Drugmaker's Unapproved Topical Scar Treatment
- IP Boutique Firm Sues Unigene Over Unpaid Fees
- Best Practices For Corporate Social Responsibility
- McCarter Boosts IP Practice With AstraZeneca In-House Atty
- GOP Sens. Blast FDA Over Reviewers' Accountability
- Pfizer Hasn't Proved Rare-Disease Drug Works, FDA Staff Says
- 7th Circ. Rejects Securities Suit Over Zimmer Hip Implant
- FDA Reviewer Backs J&J's Xarelto For Heart Condition
- Senate To Consider FDA User Fee Bill Amendments
- G-8 Hits On Drug Safety, Counterfeiting For 1st Time
- J&J Customers To Appeal Benecol False Ad Ruling
- High Court Declines 2nd Petition On Patent Evidence Limits
- Q&A With Arnold & Porter's Matthew Wolf
- Bristol, Sanofi Say Plavix Marketing Suit Isn't Supported
- Adidas Loses Injunction Bid As Herbalife Logo Battle Ends
- Applying Prometheus To Myriad: Possible Outcomes
- ViroPharma Lied About Antibiotic Exclusivity, Investor Says
- Reid Wants Monday Vote To Advance FDA User Fee Bill
- Cumberland Sues To Stop Mylan's Generic Acetadote
- Nixon Peabody Nabs Davis Wright's Health Group Vice Chair
- Va. Joins $500M Medicaid Fraud Suit Against Healthpoint
- Fenwick Snags AVI BioPharma GC For Life Sciences Practice
- FDA Issues Guidance On Biotech Pharmaceutical Testing
- Struggling J&J Unit Recalls Immodium Over Package Tears
- Royal DSM Forks Over $534M For Fish Oil Extract Co.
- Warner Chilcott Challenges Watson's Generic Contraceptive
- FDA: Show Us Your ISO Audit And We May Leave You Alone
- Q&A With Gibson Dunn's Daniel Thomasch
- On 2nd Look, Fed. Circ. Jettisons Baxter Dialysis Patent
- GOP To Wage War On ACA Regardless Of High Court Ruling
- Sanofi Units Can't Get Junk Fax Class Action Thrown Out
- Human Genome Rejects GSK's $2.6B Bid With Poison Pill
- Stiefel Must Pay Sales Rep $1.5M In ERISA, Fraud Suit
- FCC Plans Spectrum Grant For Wireless Patient Monitoring
- Cetero Purchased By Creditors In $80M Stalking Horse Deal
- Allergan Sets Up NJ Base With 93K-Square-Foot Lease
- Bayer Pays $15M To Soothe Consumers In Aspirin MDL
- Q&A With Duane Morris' Vicki Norton
- White House Endorses 'Critical' FDA User Fee Legislation
- FDA To Look At Study Linking Antibiotic To Cardiac Death
- Agilent Says $2.2B Dako Buy Will Boost Life Sciences Biz
- Patent Use Codes In The Wake Of Caraco V. Novo Nordisk
- SEC Eyes Dendreon, Possibly Over Provenge Launch
- Study Says FDA Reviews New Drugs Faster Than EU, Canada
- CalPERS' $500M Tech Property Fund Eyes Data Centers, Labs
- Feds Shut Down Off-Label Bone Graft Probe, Medtronic Says
- Allergan Sues Hi-Tech To Block Generic Lash Drug Latisse
- Senate's New FDA User Fee Bill Adds Funds For Rare Diseases
- 3rd Circ. Scraps 2 Schering Off-Label Marketing Actions
- India's Piramal Pays $635M For US Health Data Co.
- Q&A With Reed Smith's Chris Healy
- FSMA's Potential Impact, Part 1: Force Majeure Clauses
- CBO Says FDA User Fee Bill Would Save $358M Over 10 Years
- Novartis Pressures Generics Makers Over Exforge ANDA
- $100M Alzheimer's Funding Plan Includes Genentech Drug Trial
- King & Spalding Nabs Health Care Duo From Baker Donelson
- In-License Agreements With Nonprofits: 5 Considerations
- Missing Link: Food, Drug Safety In Foreign Supply Chain
- European Court Adviser Backs €53M AstraZeneca Antitrust Fine
- Q&A With Akin Gump's Dianne Elderkin
- Cardinal Agrees To Shipping Ban Over Oxycodone Orders
- Roche, Helsinn Sue Dr. Reddy's Over Bid For Generic Aloxi
- Judge Thins Malpractice Suit Over Child's Motrin Case Verdict
- NRDC Pushes To Reopen FDA Suit Over Soap Chemicals
- 41 AGs Back Bill Allowing Suits Over Generic-Drug Warnings
- FDA Urges Caution For Users Of Novartis' MS Drug
- FDA Delays Deadline For Stricter Sunscreen Labeling Rules
- Q&A With King & Spalding's Ed Basile
- Takeda Calls FCA Suit Over Unsafe Drug Interactions Baseless
- The Blurring Line Between Semi And Bio
- Hospira Recalls Overfilled Hydromorphone Injections
- Biotechs Push FDA For Clear-Cut Biosimilar Labeling Rules
- FDA Quizzed On Antibiotic Use In Corn-Based Animal Feed
- Medtronic Accused Of Off-Label Marketing Kickbacks Scheme
- New House Bill Aimed At Detecting Medical Device Risks
- GSK, Valeant Dodge Sham Patent Suit Claims In Wellbutrin Row
- Resolving Life Science Collaboration Disputes
- Canadian Ruling Puts Seroquel Suits In Limbo
- Reed Smith Snags Product Liability Guru From Dechert
- Investor Seeks To Block DSM's $360M Kensey Nash Buyout
- Q&A With Frost Brown Todd's Karlyn Schnapp
- Abbott Loses Blood Test Patent Row With Epocal
- Depomed Sues Cadila, Zydus Over Generic Gralise
- FDA Bone Drug Study Offers New Pathway For Plaintiffs
- Novartis, Lilly Rebut Indian Lawmakers' Collusion Claims
- FDA Panel Backs Approval Of Drug For HIV Prevention
- Wyeth Investors Likely To Win Class Cert. In Pristiq Case
- Medical Device Co. Accused of Artificially Inflating Stock
- FDA Panel Endorses Arena's New Obesity Drug
- State Farm Wants Out Of Pfizer Trade Dress Suit
- SEC Hits Biotech Investor With Market Manipulation Suit
- Bayer, Pharmacia To Pay $4M To Settle Superfund Suits
- Spectrum, Allos Stretch Tender Offer After FTC Info Request
- BioMed REIT Lands $92M Tenant For Empty Cambridge Lab
- FDA Targets Experimental Multiple Sclerosis Treatment
- RyMed Wins Jury Trial Over ICU's Valve Patent
- Drug Tracking Talks Continue As Panel OKs FDA Fee Bill
- Q&A With Seyfarth's John Serio
- FDA Warns Against Long-Term Use Of Osteoporosis Drugs
- The Inequitable Conduct Defense — 1 Year After Therasense
- L'Oreal Loses Botox Trademark Fight In EU
- Where Rubber Hits Road: Examples Of Alternative Fees
- Suits Against Reglan Generics Can't Skirt Mensing: NJ Court
- Fed. Circ. Finds Stroke Treatment Patent Anticipated By Study
- Notable Biotech Investor Cops To Securities Fraud
- 7th Circ. Says Admin OT Exemption Covers Pharma Sales Reps
- Sens. Allege Drugmakers Financed Opioid Misinformation
- Boston Scientific Accuses St. Jude Of Stealing Sales Data
- FDA Advisory Panel Backs Pfizer Arthritis Drug
- Kirkland Nabs 4 Kaye Scholer Pharma, Life Science Attys
- GSK Bringing $2.6B Takeover Bid To Human Genome Investors
- Unison Snags Japanese Drugmaker From Fellow PE Funds
- Q&A With Covington's Mark Lynch
- FDA Wants Child-Size Radiation Doses From Medical Imagers
- What's Next In The Myriad Genetics Case?
- RAM Faces Fines For Counterfeit, Contaminated Mesh
- Gilead's Truvada May Cut HIV Infection Risk, FDA Says
- Arena Faces New FDA Worries Over Weight-Loss Drug
- Jury Sides With Coloplast In IP Row Over Bladder Device
- Subpoenas OK In Patent Re-Exams, Cordis Tells Fed. Circ.
- FDA Panel Votes Against Approving Regeneron's Gout Drug
- FDA Says Celgene's Revlimid Tied To Higher Cancer Risks
- House Panel OKs FDA User Fees Bill Despite Sticking Points
- Savient Creditors Lose Bid To Block Debt Exchange
- Morgan Lewis Atty Sanctioned For Doc Sharing In Gene IP Row
- Mission Impossible: Impossibility Preemption Post-Levine
- Q&A With Nixon Peabody's Fred Kelly
- Top Female Trial Attorney: Reed Smith's Barbara Binis
- Device Makers Seek More Exemptions From ACA Excise Tax
- Chemist Gets 18 Months For Sanofi Trade Secrets Theft
- Reed Smith Snags Product Liability Pro From Dechert
- Shook Hardy Lures Product Liability Pro From Dechert
- Sens. Seek Study On DEA Role In Emergency Drug Shortages
- Nixon Peabody Adds Ex-Davis Wright IP Atty To LA Team
- Fed. Circ. Sides With Otsuka In Abilify Patent Validity Debate
- House Drops Potential Snag From FDA User Fee Draft Bill
- Abbott To Pay $1.6B To Settle Depakote Allegations
- Implications — And Complications — Of Undoing Mensing
- Pfizer Arthritis Drug Has Safety Risks, FDA Report Says
- Q&A With Frost Brown Todd's Steven Goldstein
- FTC 'Still In The Game' On Pay-For-Delay Challenges
- Bill Aims To Hike Penalty For Unreported Drug Trial Results
- Stryker, Racing Optics Beat Medical Face Shield Patent Row
- FDA Panel To Find If Regeneron Gout Drug's Risks Too High
- CMS Delays Sunshine Act Compliance Until Jan. 1
- Gen-Probe Shareholder Aims To Block $3.7B Hologic Deal
- Law360 Names Top Female Trial Attorneys
- Alexza's Manufacturing Issues Delay FDA Approval Of Adasuve
- Ceragenix Attacks Ousted Exec's $10M SOX Complaint
- FDA's Tightening Rein Over Foreign Clinical Trials
- Q&A With Gibbons' Estelle Tsevdos
- Genzyme Irons Out FCA Suits Over Surgery Product Marketing
- Cooley Scores Latham Capital Markets Partner In SF
- Bristol-Myers Can Seek $11M More In Stolen-Drug Insurance
- Groups Fear Obama Order Sends Excessive Power Overseas
- Haemonetics To Pay $551M For Pall's Blood Business
- Genomma Abandons $834M Prestige Brands Bid
- Wilson Sonsini Swipes Kilpatrick Townsend Patent Pro
- DOD's Drug Price Controls Unfair, DC Circ. Hears
- Boost In Reporting Cut New Drug Shortages By Half, FDA Says
- Pharma Cos. Will Open Abandoned Drugs To Outside Research
- Cleary Gottlieb Leads DSM In $360M Medical Device Co. Buy
- Takeaways From Caraco V. Novo Nordisk
- Q&A With Choate's Bill Asher
- Predictive Coding — Putting The Cart Before The Horse
- DOJ Vet With Big Biz Clients Rejoins Arnold & Porter
- 1st Circ. Affirms $26M Award In Sulindac Injury Suit
- Doctors Speak Out Against FDA's Plan For More OTC Drugs
- Q&A With Robins Kaplan's Matthew McFarlane
- J&J China Enters Medical Device Market With Bioseal Buy
- Jackson Lewis Snags Merck's International Labor Chief
- Prometheus Dooms DNA Analysis Patent, Merial Claims
- Mylan Denied Invalidity In Cancer Drug IP Battle
- FDA Loosens Sterility Testing Rules For Biologics
- The Uncertain Fate Of Learned Intermediary Doctrine
- Addressing Breach Of Method-Of-Use Patents By Generics
- Ill. Appeals Court Rejects Abbott's Bid To Move Class Action
- FDA Drug Reviews Pass Muster As User Fee Deadline Looms
- Big Biz Hails Obama's Order To Align International Regs
- FDA Urged To Require Ongoing Safety Checks For Risky Drugs
- St. Jude's Device Liability May Not End With Recalls: Report
- FDA Revised Benefit-Risk Criteria — Embracing Innovation
- Hospira Blocks Sandoz's Generic Precedex
- Pfizer Settles BYU's Long-Running Celebrex Suit
- 6th Circ. Won't Overturn Fen-Phen Attys' Convictions
- Creditor Sues Savient Pharmaceuticals To Force Liquidation
- Q&A With Reed Smith's Melissa Geist
- Chattem Concealed Carcinogen In Dexatrim, Suit Says